Generic Drug Review June 2008

Pharmaceuticals are a large part of health care expenditures in the United States.

Pharmacists should be familiar with the legal issues involved when they dispense a drug manufactured by a company other than the one that makes the brand name of the prescribed drug.

One of GPhA's priorities is to establish a workable FDA approval pathway that provides timely access to safe and affordable biogenerics to Americans in need of these life-saving medicines.

While the November presidential and congressional elections are still many months away, it is widely expected that health care reform will be at the top of the domestic policy agenda in the upcoming fall campaign.

There is little debate that the Rx-to-OTC switch movement (when a prescription drug is reclassified to nonprescription or OTC status) has caused major changes in the pharmacy marketplace.